Novo Nordisk A/S Asset Resilience Ratio
Novo Nordisk A/S asset resilience ratio. Novo Nordisk A/S (NOVO-B) has an Asset Resilience Ratio of 0.09% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Novo Nordisk A/S defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Novo Nordisk A/S (2001–2025)
Asset resilience ratio of Novo Nordisk A/S from 2001 to 2025. This chart shows how Novo Nordisk A/S's Asset Resilience Ratio has changed over time. Read how much debt does Novo Nordisk A/S carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Novo Nordisk A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Novo Nordisk A/S.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr498.00 Million | 0.09% |
| Total Liquid Assets | Dkr498.00 Million | 0.09% |
Asset Resilience Insights
- Limited Liquidity: Novo Nordisk A/S maintains only 0.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Novo Nordisk A/S Industry Peers by Asset Resilience Ratio
Compare Novo Nordisk A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 0.00% |
|
Organon & Co
NYSE:OGN |
Drug Manufacturers - General | 4.46% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
Novo Nordisk A/S Asset Resilience Ratio by Year (2001–2025)
Novo Nordisk A/S asset resilience ratio by year from 2001 to 2025. The table below shows the annual Asset Resilience Ratio data for Novo Nordisk A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.09% | Dkr498.00 Million ≈ $77.92 Million |
Dkr542.90 Billion ≈ $84.94 Billion |
-2.20pp |
| 2024-12-31 | 2.29% | Dkr10.65 Billion ≈ $1.67 Billion |
Dkr465.80 Billion ≈ $72.88 Billion |
-2.75pp |
| 2023-12-31 | 5.04% | Dkr15.84 Billion ≈ $2.48 Billion |
Dkr314.49 Billion ≈ $49.20 Billion |
-4.74pp |
| 2022-12-31 | 9.77% | Dkr23.57 Billion ≈ $3.69 Billion |
Dkr241.26 Billion ≈ $37.75 Billion |
+0.78pp |
| 2021-12-31 | 8.99% | Dkr17.48 Billion ≈ $2.74 Billion |
Dkr194.51 Billion ≈ $30.43 Billion |
+0.19pp |
| 2020-12-31 | 8.80% | Dkr12.76 Billion ≈ $2.00 Billion |
Dkr144.92 Billion ≈ $22.67 Billion |
-3.52pp |
| 2019-12-31 | 12.32% | Dkr15.47 Billion ≈ $2.42 Billion |
Dkr125.61 Billion ≈ $19.65 Billion |
-1.80pp |
| 2018-12-31 | 14.12% | Dkr15.64 Billion ≈ $2.45 Billion |
Dkr110.77 Billion ≈ $17.33 Billion |
-6.55pp |
| 2017-12-31 | 20.67% | Dkr21.16 Billion ≈ $3.31 Billion |
Dkr102.36 Billion ≈ $16.01 Billion |
-0.55pp |
| 2016-12-31 | 21.22% | Dkr20.70 Billion ≈ $3.24 Billion |
Dkr97.54 Billion ≈ $15.26 Billion |
-1.07pp |
| 2015-12-31 | 22.29% | Dkr20.46 Billion ≈ $3.20 Billion |
Dkr91.80 Billion ≈ $14.36 Billion |
+1.65pp |
| 2014-12-31 | 20.64% | Dkr15.90 Billion ≈ $2.49 Billion |
Dkr77.06 Billion ≈ $12.06 Billion |
+0.07pp |
| 2013-12-31 | 20.57% | Dkr14.47 Billion ≈ $2.26 Billion |
Dkr70.34 Billion ≈ $11.00 Billion |
-3.95pp |
| 2012-12-31 | 24.52% | Dkr16.11 Billion ≈ $2.52 Billion |
Dkr65.67 Billion ≈ $10.27 Billion |
-2.53pp |
| 2011-12-31 | 27.05% | Dkr17.50 Billion ≈ $2.74 Billion |
Dkr64.70 Billion ≈ $10.12 Billion |
+0.91pp |
| 2010-12-31 | 26.14% | Dkr16.05 Billion ≈ $2.51 Billion |
Dkr61.40 Billion ≈ $9.61 Billion |
+2.71pp |
| 2009-12-31 | 23.43% | Dkr12.83 Billion ≈ $2.01 Billion |
Dkr54.74 Billion ≈ $8.56 Billion |
+3.35pp |
| 2008-12-31 | 20.08% | Dkr10.18 Billion ≈ $1.59 Billion |
Dkr50.73 Billion ≈ $7.94 Billion |
+4.63pp |
| 2007-12-31 | 15.45% | Dkr7.38 Billion ≈ $1.16 Billion |
Dkr47.80 Billion ≈ $7.48 Billion |
+4.03pp |
| 2006-12-31 | 11.42% | Dkr5.10 Billion ≈ $798.32 Million |
Dkr44.70 Billion ≈ $6.99 Billion |
-0.56pp |
| 2005-12-31 | 11.98% | Dkr5.02 Billion ≈ $785.10 Million |
Dkr41.90 Billion ≈ $6.55 Billion |
+1.39pp |
| 2004-12-31 | 10.58% | Dkr3.99 Billion ≈ $624.21 Million |
Dkr37.70 Billion ≈ $5.90 Billion |
+1.60pp |
| 2003-12-31 | 8.98% | Dkr3.10 Billion ≈ $484.74 Million |
Dkr34.49 Billion ≈ $5.40 Billion |
+3.45pp |
| 2002-12-31 | 5.54% | Dkr1.74 Billion ≈ $272.41 Million |
Dkr31.45 Billion ≈ $4.92 Billion |
+0.70pp |
| 2001-12-31 | 4.84% | Dkr1.40 Billion ≈ $218.28 Million |
Dkr28.83 Billion ≈ $4.51 Billion |
-- |
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products i… Read more